Stakeholders:
Natalie Kuzla, Program Manager for PRECINCT
Jim Dattilo, Senior Clinical Data Manger for PRECINCT
Qi Long, PI
Nicola (Nikki) Mason
Data Types Collected:
Data collected in PRECINCT:
Clinical trial data/observations
Genomic DNA sequence (including cfDNA) – WES, WGS
RNA sequence
qRT-PCR (e.g. for cytokines)
Flow cytometry (surface antigens for tumor and immune phenotyping, intracellular markers and cytokines)
Immunohistochemistry (tumor, LN biopsies)
Cytokine/chemokine levels (ELISA, EliSpot)
Imaging – MRI, PET
Proliferation assays (CFSE)
Cytotoxicity assays (51Cr release)
ADCC assays
Virus Titers (HSV)
https://dctd.cancer.gov/NewsEvents/20190327_canine_immunotherapy.htm
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies
Mason, Nicola J. Propert, Kathleen Joy
University of Pennsylvania, Philadelphia, PA, United Stateshttps://deainfo.nci.nih.gov/advisory/bsa/1016/1_CanineTrials.pdf (Description of UM1/U24 grants and relationships)
U24 Holder - Data Coordinating Center for U01 Holders
in cooperation with NCI COP and NCI program staff:
•Help develop and implement clinical studies
•Assist in standardization of clinical and laboratory protocols
•Manage clinical and correlative data and provide statistical support
•Facilitate sharing of agent, specimens and data
Institution | Project Leader(s) | Canine Cancer(s) |
U Penn | Nicola Mason/Kathleen Propert | U24 coordinating center |
- Collecting data in the following areas:
- Clinical trial data/observations
- Genomic DNA sequence (including cfDNA) – WES, WGS
- RNA sequence
- qRT-PCR (e.g. for cytokines)
- Flow cytometry (surface antigens for tumor and immune phenotyping, intracellular markers and cytokines)
- Immunohistochemistry (tumor, LN biopsies)
- Cytokine/chemokine levels (ELISA, EliSpot)
- Imaging – MRI, PET
- Proliferation assays (CFSE)
- Cytotoxicity assays (51Cr release)
- ADCC assays
- Virus Titers (HSV)
UM1 Holders - Clinical Data
•Conduct canine clinical trials using immunotherapeutic agents and novel combinations
•Correlative studies to characterize and understand the cellular and molecular mechanisms that determine response (or non-response)
Institution | Project Leader(s) | Canine Cancer(s) |
Colorado State U | Steven Dow/Cheryl London | Osteosarcoma, novel immunotherapy combinations |
U of Alabama at Birmingham | MR Chambers | Glioma, immuno-neurotherapeutics |
U of Minnesota | Grace Elizabeth Pluhar | Glioma, immunotherapy combinations |
UC Davis | Robert Canter/Robert Rebhun | Melanoma and osteosarcoma, NK immunotherapy |
Tufts U | Cheryl London/Kristy Richards | B-cell lymphoma, immunotherapy combinations |
